BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome

Andrea Visentin, Silvia Imbergamo, Edoardo Scomazzon, Stefano Pravato, Federica Frezzato, Laura Bonaldi, Marco Pizzi, Stefania Vio, Michele Gregianin, Marta Burei, Monica Facco, Gianpietro Semenzato, Francesco Piazza, Livio Trentin

Research output: Contribution to journalArticle

1 Citation (Scopus)
Original languageEnglish
Number of pages4
JournalBritish Journal of Haematology
DOIs
Publication statusE-pub ahead of print - Jul 5 2018

Keywords

  • Chronic lymphocytic leukaemia
  • Ibrutinib
  • Idelalisib
  • Lenalidomide
  • Richter syndrome

ASJC Scopus subject areas

  • Hematology

Cite this

BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. / Visentin, Andrea; Imbergamo, Silvia; Scomazzon, Edoardo; Pravato, Stefano; Frezzato, Federica; Bonaldi, Laura; Pizzi, Marco; Vio, Stefania; Gregianin, Michele; Burei, Marta; Facco, Monica; Semenzato, Gianpietro; Piazza, Francesco; Trentin, Livio.

In: British Journal of Haematology, 05.07.2018.

Research output: Contribution to journalArticle

Visentin, A, Imbergamo, S, Scomazzon, E, Pravato, S, Frezzato, F, Bonaldi, L, Pizzi, M, Vio, S, Gregianin, M, Burei, M, Facco, M, Semenzato, G, Piazza, F & Trentin, L 2018, 'BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome', British Journal of Haematology. https://doi.org/10.1111/bjh.15440
Visentin, Andrea ; Imbergamo, Silvia ; Scomazzon, Edoardo ; Pravato, Stefano ; Frezzato, Federica ; Bonaldi, Laura ; Pizzi, Marco ; Vio, Stefania ; Gregianin, Michele ; Burei, Marta ; Facco, Monica ; Semenzato, Gianpietro ; Piazza, Francesco ; Trentin, Livio. / BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. In: British Journal of Haematology. 2018.
@article{ed2f640fbfc64b218910619b65214208,
title = "BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome",
keywords = "Chronic lymphocytic leukaemia, Ibrutinib, Idelalisib, Lenalidomide, Richter syndrome",
author = "Andrea Visentin and Silvia Imbergamo and Edoardo Scomazzon and Stefano Pravato and Federica Frezzato and Laura Bonaldi and Marco Pizzi and Stefania Vio and Michele Gregianin and Marta Burei and Monica Facco and Gianpietro Semenzato and Francesco Piazza and Livio Trentin",
year = "2018",
month = "7",
day = "5",
doi = "10.1111/bjh.15440",
language = "English",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",

}

TY - JOUR

T1 - BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome

AU - Visentin, Andrea

AU - Imbergamo, Silvia

AU - Scomazzon, Edoardo

AU - Pravato, Stefano

AU - Frezzato, Federica

AU - Bonaldi, Laura

AU - Pizzi, Marco

AU - Vio, Stefania

AU - Gregianin, Michele

AU - Burei, Marta

AU - Facco, Monica

AU - Semenzato, Gianpietro

AU - Piazza, Francesco

AU - Trentin, Livio

PY - 2018/7/5

Y1 - 2018/7/5

KW - Chronic lymphocytic leukaemia

KW - Ibrutinib

KW - Idelalisib

KW - Lenalidomide

KW - Richter syndrome

UR - http://www.scopus.com/inward/record.url?scp=85050633169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050633169&partnerID=8YFLogxK

U2 - 10.1111/bjh.15440

DO - 10.1111/bjh.15440

M3 - Article

AN - SCOPUS:85050633169

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -